Houston-based Motif plans for its RESONATE early feasibility study to evaluate its Motif XCS wirelessly powered implant. Motif XCS, built on the company’s DOT microstimulator technology, delivers gentle electrical stimulation to a brain region clinically shown to reduce the symptoms of depression in adults who have not found relief from two or more medications.

The company says the milestone makes it the fastest implantable brain-computer interface (BCI) company to move from founding to IDE approval with a novel device, picking up the FDA nod four years after its establishment. It launched a patient registry for the technology late last year.